Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244933 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
A Phase 2 study, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT00244933 is a Phase 2 study that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT00244933, a Phase 2 study, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and genistein, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine hydrochloride together with genistein may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine hydrochloride together with genistein works in treating women with stage IV breast cancer.
Interventions
- PROCEDURE Tumor biopsy
- DRUG gemcitabine
- DIETARY_SUPPLEMENT genistein
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-02 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244933
The ClinicalTrials.gov registry entry for NCT00244933 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Tumor biopsy is the first listed.
NCT00244933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244933 about?
NCT00244933 is a clinical study titled "Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and genistein, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving gemcitabine hydrochloride together with genistein may kill more tumor cells. PURPOS...
What is the current status of trial NCT00244933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2004-02. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00244933?
The interventions under investigation include: Tumor biopsy (PROCEDURE), gemcitabine (DRUG), genistein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00244933?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.